Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Asset Writedowns and Impairment (2016 - 2025)

Veracyte's Asset Writedowns and Impairment history spans 10 years, with the latest figure at $20.5 million for Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $20.5 million; the TTM value through Dec 2025 reached $20.5 million, up 508.67%, while the annual FY2025 figure was $20.5 million, 508.67% up from the prior year.
  • Asset Writedowns and Impairment for Q2 2025 was $20.5 million at Veracyte, up from $2.8 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $34.9 million in Q3 2023 and bottomed at $185000.0 in Q3 2024.
  • The 4-year median for Asset Writedowns and Impairment is $3.0 million (2022), against an average of $11.9 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 69.36% in 2024 against a maximum downside of 99.47% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $3.3 million in 2022, then surged by 865.91% to $32.0 million in 2023, then plummeted by 91.41% to $2.8 million in 2024, then surged by 644.37% to $20.5 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Asset Writedowns and Impairment are $20.5 million (Q2 2025), $2.8 million (Q4 2024), and $185000.0 (Q3 2024).